论文部分内容阅读
Background and Objective Cyclosporine A (CsA) has been used as immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation (HSCT) for about 30 years.Recently, Tacrolimus (FK506) is increasingly used in this clinical condition and pharmacological studies indicate that FK506 might be more effective than CsA.However, data on the comparison of these two drugs has been conflicting across clinical studies.Therefore, we compared the efficacy and safety of CsA versus FK506 as post-allogeneic HSCT immunosuppressive therapy.